FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207556> ?p ?o ?g. }

• W4387207556 endingPage "S47" @default.
• W4387207556 startingPage "S47" @default.
• W4387207556 abstract "Accelerated partial breast irradiation (APBI) after breast conserving therapy (BCT) is increasingly used to treat women with early stage breast cancer. Our institution was an early adopter of 5-fraction ABPI and delivers APBI primarily to patients in the prone position. This study reports long term oncologic and cosmetic outcome in a large cohort of women treated with 5-fraction external beam APBI.We included patients receiving APBI 600 cGy × 5 fx delivered every other day or every day between 2010 and 2022. Late toxicities and clinician and patient rated cosmesis were evaluated for patients with > 6 month follow up. Univariate and multivariate logistic regression models were used to identify clinical and dosimetric factors associated with development of acute and late toxicities, clinician and patient rated cosmesis. All statistical tests were two-sided, and the null hypothesis was rejected for p<0.05. Kaplan Meier methodology was used to calculate overall survival (OS), disease-free survival (DFS) and locoregional recurrence-free survival (LR-RFS).Four hundred and forty-two patients received APBI either daily (56%) or every other day (44%). Most of the patients (92%) were treated in the prone position. Average mean heart dose was 23 cGy for left-sided and 11 cGy for right-sided breast cancers. Ipsilateral lung V30% ≤ 30%. At a median follow up of 48 months (range: 5.96 - 155 months), 12 (2.7%) patients developed a local recurrence, 14 (3.2%) patients developed a contralateral breast primary, 10 patients (2.3%) developed a distant metastasis and one patient (0.2%) developed a local recurrence followed by a distant metastasis 1 month later. Out of 258 patients with > 6 month follow up, rates of late grade 1-2 telangiectasia, fibrosis, edema, atrophy and hyperpigmentation were 4%, 18%, 1%, 19% and 7% respectively. There was only one late grade 3 event in a patient who developed significant breast atrophy. The rate of good-excellent physician and patient rated cosmesis was 95% and 89% respectively (N = 256 at median follow up of 80 months). On multivariate logistic regression, patients who did not receive any adjuvant endocrine or chemotherapy were at increased risk of developing a local recurrence. Patients with PR negative disease were at increased risk of distant metastasis. Patient who experienced any grade of acute dermatitis during treatment were at increased risk of any high grade (grade ≥ 2) late adverse event and worse physician rated cosmesis. Daily or every other day treatment did not correlate with worse toxicity or clinical outcomes. Plastic surgery involvement, LVI, EIC, lobular histology, and ER negativity did not correlate with an increased risk of recurrence. Five-year LR-RFS, DFS and OS were 98%, 92.5% and 98.6% respectively.Five- fraction APBI delivered primarily in the prone position either daily or every other day was effective with low rates of local recurrence, minimal toxicity and excellent cosmetic scores at long term follow up." @default.
• W4387207556 created "2023-09-30" @default.
• W4387207556 creator A5005084337 @default.
• W4387207556 creator A5019811619 @default.
• W4387207556 creator A5022528926 @default.
• W4387207556 creator A5024436099 @default.
• W4387207556 creator A5035762260 @default.
• W4387207556 creator A5045890439 @default.
• W4387207556 creator A5052498725 @default.
• W4387207556 creator A5058616337 @default.
• W4387207556 creator A5059530383 @default.
• W4387207556 creator A5062484027 @default.
• W4387207556 creator A5063826729 @default.
• W4387207556 creator A5077793009 @default.
• W4387207556 creator A5089929569 @default.
• W4387207556 date "2023-10-01" @default.
• W4387207556 modified "2023-10-04" @default.
• W4387207556 title "Effectiveness and Toxicity of Five Fraction Prone Accelerated Partial Breast Irradiation" @default.
• W4387207556 doi "https://doi.org/10.1016/j.ijrobp.2023.06.326" @default.
• W4387207556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784507" @default.
• W4387207556 hasPublicationYear "2023" @default.
• W4387207556 type Work @default.
• W4387207556 citedByCount "0" @default.
• W4387207556 crossrefType "journal-article" @default.
• W4387207556 hasAuthorship W4387207556A5005084337 @default.
• W4387207556 hasAuthorship W4387207556A5019811619 @default.
• W4387207556 hasAuthorship W4387207556A5022528926 @default.
• W4387207556 hasAuthorship W4387207556A5024436099 @default.
• W4387207556 hasAuthorship W4387207556A5035762260 @default.
• W4387207556 hasAuthorship W4387207556A5045890439 @default.
• W4387207556 hasAuthorship W4387207556A5052498725 @default.
• W4387207556 hasAuthorship W4387207556A5058616337 @default.
• W4387207556 hasAuthorship W4387207556A5059530383 @default.
• W4387207556 hasAuthorship W4387207556A5062484027 @default.
• W4387207556 hasAuthorship W4387207556A5063826729 @default.
• W4387207556 hasAuthorship W4387207556A5077793009 @default.
• W4387207556 hasAuthorship W4387207556A5089929569 @default.
• W4387207556 hasConcept C121608353 @default.
• W4387207556 hasConcept C126322002 @default.
• W4387207556 hasConcept C126838900 @default.
• W4387207556 hasConcept C141071460 @default.
• W4387207556 hasConcept C144301174 @default.
• W4387207556 hasConcept C146357865 @default.
• W4387207556 hasConcept C151730666 @default.
• W4387207556 hasConcept C163100246 @default.
• W4387207556 hasConcept C2780943399 @default.
• W4387207556 hasConcept C2989005 @default.
• W4387207556 hasConcept C38180746 @default.
• W4387207556 hasConcept C50382708 @default.
• W4387207556 hasConcept C509974204 @default.
• W4387207556 hasConcept C530470458 @default.
• W4387207556 hasConcept C71924100 @default.
• W4387207556 hasConcept C72563966 @default.
• W4387207556 hasConcept C86803240 @default.
• W4387207556 hasConceptScore W4387207556C121608353 @default.
• W4387207556 hasConceptScore W4387207556C126322002 @default.
• W4387207556 hasConceptScore W4387207556C126838900 @default.
• W4387207556 hasConceptScore W4387207556C141071460 @default.
• W4387207556 hasConceptScore W4387207556C144301174 @default.
• W4387207556 hasConceptScore W4387207556C146357865 @default.
• W4387207556 hasConceptScore W4387207556C151730666 @default.
• W4387207556 hasConceptScore W4387207556C163100246 @default.
• W4387207556 hasConceptScore W4387207556C2780943399 @default.
• W4387207556 hasConceptScore W4387207556C2989005 @default.
• W4387207556 hasConceptScore W4387207556C38180746 @default.
• W4387207556 hasConceptScore W4387207556C50382708 @default.
• W4387207556 hasConceptScore W4387207556C509974204 @default.
• W4387207556 hasConceptScore W4387207556C530470458 @default.
• W4387207556 hasConceptScore W4387207556C71924100 @default.
• W4387207556 hasConceptScore W4387207556C72563966 @default.
• W4387207556 hasConceptScore W4387207556C86803240 @default.
• W4387207556 hasIssue "2" @default.
• W4387207556 hasLocation W43872075561 @default.
• W4387207556 hasLocation W43872075562 @default.
• W4387207556 hasOpenAccess W4387207556 @default.
• W4387207556 hasPrimaryLocation W43872075561 @default.
• W4387207556 hasRelatedWork W2013727445 @default.
• W4387207556 hasRelatedWork W2354584592 @default.
• W4387207556 hasRelatedWork W2363865786 @default.
• W4387207556 hasRelatedWork W2374376758 @default.
• W4387207556 hasRelatedWork W2411442805 @default.
• W4387207556 hasRelatedWork W2415741046 @default.
• W4387207556 hasRelatedWork W274490372 @default.
• W4387207556 hasRelatedWork W2784206856 @default.
• W4387207556 hasRelatedWork W2948913314 @default.
• W4387207556 hasRelatedWork W93388018 @default.
• W4387207556 hasVolume "117" @default.
• W4387207556 isParatext "false" @default.
• W4387207556 isRetracted "false" @default.
• W4387207556 workType "article" @default.